John C. Byrd
About
John C. Byrd is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology.
According to data from OpenAlex, John C. Byrd has authored 701 papers receiving a total of 28.1k indexed citations (citations by other indexed papers that have themselves been cited), including 526 papers in Genetics, 234 papers in Pathology and Forensic Medicine and 224 papers in Hematology. Recurrent topics in John C. Byrd's work include Chronic Lymphocytic Leukemia Research (508 papers), Lymphoma Diagnosis and Treatment (228 papers) and Acute Myeloid Leukemia Research (122 papers). John C. Byrd is often cited by papers focused on Chronic Lymphocytic Leukemia Research (508 papers), Lymphoma Diagnosis and Treatment (228 papers) and Acute Myeloid Leukemia Research (122 papers). John C. Byrd collaborates with scholars based in United States, United Kingdom and Italy. John C. Byrd's co-authors include Amy J. Johnson, Jennifer A. Woyach, Michael R. Grever, Joseph M. Flynn, Nyla A. Heerema, Kristie A. Blum, Jeffrey A. Jones, Thomas J. Kipps, Thomas S. Lin and Leslie A. Andritsos and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.
In The Last Decade
John C. Byrd
679 papers receiving 27.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| John C. Byrd United States | 82 | 15.1k | 10.6k | 9.3k | 9.3k | 7.9k | 701 | 28.1k | ||
| William G. Wierda United States | 88 | 18.2k 1.2× | 13.0k 1.2× | 8.5k 0.9× | 11.0k 1.2× | 8.2k 1.0× | 829 | 31.7k | ||
| Jan A. Burger United States | 78 | 12.9k 0.9× | 8.5k 0.8× | 5.4k 0.6× | 6.1k 0.7× | 7.8k 1.0× | 431 | 20.9k | ||
| John G. Gribben United Kingdom | 89 | 9.2k 0.6× | 8.8k 0.8× | 5.0k 0.5× | 5.1k 0.5× | 10.9k 1.4× | 481 | 24.1k | ||
| Stephan Stilgenbauer Germany | 75 | 16.2k 1.1× | 12.9k 1.2× | 6.2k 0.7× | 3.5k 0.4× | 7.8k 1.0× | 517 | 23.5k | ||
| Tadeusz Robak Poland | 59 | 10.0k 0.7× | 7.8k 0.7× | 5.3k 0.6× | 5.8k 0.6× | 5.3k 0.7× | 712 | 19.3k | ||
| Thomas J. Kipps United States | 91 | 19.7k 1.3× | 13.2k 1.3× | 11.7k 1.3× | 5.0k 0.5× | 14.8k 1.9× | 622 | 35.2k | ||
| Daniel Catovsky United Kingdom | 83 | 19.4k 1.3× | 13.6k 1.3× | 7.2k 0.8× | 14.6k 1.6× | 10.3k 1.3× | 529 | 35.2k | ||
| Maher Albitar United States | 65 | 8.2k 0.5× | 4.3k 0.4× | 7.5k 0.8× | 9.2k 1.0× | 3.4k 0.4× | 342 | 20.0k | ||
| R. Kanti United States | 61 | 16.0k 1.1× | 11.4k 1.1× | 7.2k 0.8× | 2.9k 0.3× | 9.0k 1.1× | 281 | 23.3k | ||
| Hartmut Döhner Germany | 101 | 19.0k 1.3× | 12.1k 1.1× | 17.5k 1.9× | 21.1k 2.3× | 9.5k 1.2× | 653 | 44.9k |
Countries citing papers authored by John C. Byrd
Since
Specialization
Citations
This map shows the geographic impact of John C. Byrd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John C. Byrd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John C. Byrd more than expected).
Fields of papers citing papers by John C. Byrd
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by John C. Byrd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John C. Byrd. The network helps show where John C. Byrd may publish in the future.
Co-authorship network of co-authors of John C. Byrd
This figure shows the co-authorship network connecting the top 25 collaborators of John C. Byrd. A scholar is included among the top collaborators of John C. Byrd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John C. Byrd. John C. Byrd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kohlschmidt, Jessica, Krzysztof Mrózek, Deedra Nicolet, et al.. (2023). Association of social deprivation with survival in younger adult patients with AML: an Alliance study. Blood Advances. 7(15). 4019–4023.
2.
Woyach, Jennifer A., James S. Blachly, Kerry A. Rogers, et al.. (2020). Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood. 136(Supplement 1). 16–18.
3.
Byrd, John C., Richard R. Furman, Steven Coutré, et al.. (2020). Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. Clinical Cancer Research. 26(15). 3918–3927.
4.
Woyach, Jennifer A., James S. Blachly, Kerry A. Rogers, et al.. (2020). Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia. Cancer Discovery. 10(3). 394–405.
5.
Thangavadivel, Shanmugapriya, Qiuhong Zhao, Narendranath Epperla, et al.. (2020). Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. Clinical Cancer Research. 26(23). 6187–6195.
6.
Rogers, Kerry A., Ying Huang, Farrukh T. Awan, et al.. (2017). Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia. Blood. 130. 431–431.
7.
Campbell, Amanda R., Megan Duggan, Lorena P. Suarez‐Kelly, et al.. (2017). MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions. Cancer Immunology Research. 5(9). 778–789.
8.
Brown, Fiona C., Paolo Cifani, Esther Drill, et al.. (2016). Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. British Journal of Haematology. 176(1). 86–91.
9.
Lozanski, Gerard, et al.. (2016). MuCor: mutation aggregation and correlation. Bioinformatics. 32(10). 1557–1558.
10.
Gupta, Nikhil, Jeffrey A. Jones, Xiaokui Mo, et al.. (2016). Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells. Cancer Immunology Research. 4(8). 698–707.
11.
Herman, Sarah E. M., Arnau Montraveta, Carsten Utoft Niemann, et al.. (2016). The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Clinical Cancer Research. 23(11). 2831–2841.
12.
Hing, Zachary A., Rose Mantel, Kyle A. Beckwith, et al.. (2015). Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. Blood. 125(20). 3128–3132.
13.
Fiskus, Warren, Nakhle S. Saba, Min Shen, et al.. (2014). Auranofin Induces Lethal Oxidative and Endoplasmic Reticulum Stress and Exerts Potent Preclinical Activity against Chronic Lymphocytic Leukemia. Cancer Research. 74(9). 2520–2532.
14.
Huang, Xiaomeng, Sebastian Schwind, Bo Yu, et al.. (2013). Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia. Clinical Cancer Research. 19(9). 2355–2367.
15.
Oakes, Christopher C., Rainer Claus, Lei Gu, et al.. (2013). Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia. Cancer Discovery. 4(3). 348–361.
16.
Ji, Jia, Diane R. Mould, Kristie A. Blum, et al.. (2013). A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol. Clinical Cancer Research. 19(5). 1269–1280.
17.
Woyach, Jennifer A., Amy S. Ruppert, Nyla A. Heerema, et al.. (2011). Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712. Journal of Clinical Oncology. 29(10). 1349–1355.
18.
Ni, Wenjun, Jia Ji, Zunyan Dai, et al.. (2010). Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition. PLoS ONE. 5(11). e13792–e13792.
19.
Blum, William, Rebecca B. Klisovic, Heiko Becker, et al.. (2010). Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias. Journal of Clinical Oncology. 28(33). 4919–4925.
20.
Benson, Don M., Courtney E. Bakan, Anjali Mishra, et al.. (2010). The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody. Blood. 116(13). 2286–2294.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by William G. Wierda Breakdown of academic impact, for papers by Jan A. Burger Breakdown of academic impact, for papers by John G. Gribben Breakdown of academic impact, for papers by Stephan Stilgenbauer Breakdown of academic impact, for papers by Tadeusz Robak Breakdown of academic impact, for papers by Thomas J. Kipps Breakdown of academic impact, for papers by Daniel Catovsky Breakdown of academic impact, for papers by Maher Albitar Breakdown of academic impact, for papers by R. Kanti Breakdown of academic impact, for papers by Hartmut Döhner